Shattuck Labs is a clinical-stage biotech with a preclinical pipeline, resulting in zero revenue over the last six quarters and a consistent quarterly cash burn exceeding $12M. The company's balance sheet was recently fortified with a capital raise, bringing c...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | -$0.12+3.3% vs -$0.12 | — vs — |
Q2 2026 May 7, 2026 | -$0.13+7.1% vs -$0.14 | — vs — |
Q2 2026 Mar 5, 2026 | -$0.12+0.0% vs -$0.12 | — vs $250,000 |
Q4 2025 Nov 6, 2025 | -$0.14+6.7% vs -$0.15 | $1M+500.0% vs $166,670 |
Frazier Life Sciences Management L.P. bought a new position in shares of Shattuck Labs, Inc. (NASDAQ: STTK) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,750,000 shares of the company's stock, valued at approximately $26,025,000. Frazier Life Sciences Management L.P. owned 3.74%
BlackRock Inc. purchased a new stake in Shattuck Labs, Inc. (NASDAQ: STTK) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 3,935,810 shares of the company's stock, valued at approximately $27,315,000. BlackRock Inc. owned about 5.13% of Shattuck Labs as of its
AUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences:
Shattuck Labs pivots to immunology, focusing on DR3-targeted therapies for IBD, notably SL-325, after discontinuing its oncology program. SL-325's Phase 1 data show strong safety, low immunogenicity (3.7% ADA rate), and durable receptor occupancy, supporting quarterly dosing potential. STTK is fully funded through Phase 2b efficacy readout, with cash runway into 2029 despite significant dilution; valuation trades at a forward price-to-book discount.
Benchmark STTK against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Shattuck Labs, Inc. (STTK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.36 | $574.77M | -9.09 | -82.52% | -4880.9% | -60.25% | — | |
| $26.39 | $3.32B | -8.02 | -4.26% | -386.32% | -87.98% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $8.40 | $349.8M | -2470.59 | 10.37% | 69.76% | — | — | |
| $2.76 | $197.47M | -1.96 | — | — | -39.64% | — | |
| $0.95 | $1.86M | -0.08 | -13.43% | -490.33% | -1035.26% | — |
Shattuck Labs, Inc. (STTK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Shattuck Labs, Inc. (STTK) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Jun 11, 2026·SEC
Jun 9, 2026·SEC
Get notified when STTK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Shattuck Labs, Inc. (STTK) stock FAQ — growth, dividends, profitability & financials explained
Shattuck Labs, Inc. (STTK) reported $1.0M in revenue for fiscal year 2025. This represents a 96% decrease from $22.4M in 2018.
Shattuck Labs, Inc. (STTK) saw revenue decline by 82.5% over the past year.
Shattuck Labs, Inc. (STTK) reported a net loss of $52.6M for fiscal year 2025.
Shattuck Labs, Inc. (STTK) has a return on equity (ROE) of -60.3%. Negative ROE indicates the company is unprofitable.
Shattuck Labs, Inc. (STTK) had negative free cash flow of $41.2M in fiscal year 2025, likely due to heavy capital investments.
